ALPHAMAB ONCOLOGY
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment with multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/ immunology, and they are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally.
ALPHAMAB ONCOLOGY
Social Links:
Industry:
Biotechnology Clinical Trials Health Care Manufacturing Oncology Pharmaceutical Therapeutics
Founded:
2009-01-01
Status:
Active
Contact:
+86-512 6285 0800
Email Addresses:
[email protected]
Total Funding:
160 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro SPF SSL By Default Mobile Non Scaleable Content Pound Sterling ASP.NET IIS
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Apollo 24/7
Apollo 24|7 is a mobile app and digital healthcare platform.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
BiolineRx
BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel.
Medannex Ltd
Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1.
Median Technologies
MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, screening, and clinical practice.
Soothe Healthcare
Soothe Healthcare is an engaged in manufacturing, marketing & distributing Consumer-Healthcare products.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
PAG
PAG investment in Series B - Alphamab Oncology
China Venture Capital
China Venture Capital investment in Series B - Alphamab Oncology
Hudson Bay Capital Management
Hudson Bay Capital Management investment in Series B - Alphamab Oncology
Adrian Cheng
Adrian Cheng investment in Series B - Alphamab Oncology
Advantech Capital
Advantech Capital investment in Series B - Alphamab Oncology
Advantech Capital
Advantech Capital investment in Series A - Alphamab Oncology
Heritage Provider Network
Heritage Provider Network investment in Series A - Alphamab Oncology
China Venture Capital
China Venture Capital investment in Series A - Alphamab Oncology
OrbiMed
OrbiMed investment in Series A - Alphamab Oncology
PAG
PAG investment in Series A - Alphamab Oncology
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-03-01 | Sidi Diagnostics | Alphamab Oncology investment in Venture Round - Sidi Diagnostics | 280 M CNY |
| 2016-03-21 | SmartNuclide | Alphamab Oncology investment in Angel Round - SmartNuclide | 3 M CNY |
More informations about "Alphamab Oncology"
Alphamab Oncology - Crunchbase Investor Profile & Investments
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for …See details»
Alphamab Oncology - Funding, Financials, Valuation & Investors
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization. Search Crunchbase. ... How much …See details»
Alphamab Oncology: Revenue, Worth, Valuation & Competitors …
About Alphamab Oncology. Alphamab Oncology is a Pharmaceuticals related company founded in 2015 with 30 employees an estimated revenue of $6M, and. It has 10 competitors including …See details»
Alphamab Oncology Presentation
Alphamab Oncology Presentation January 2021. Disclaimer This presentation has been prepared by Alphamab Oncology (the “Company”)solely for use at the presentation held in January …See details»
Alphamab Oncology - Products, Competitors, Financials, …
Dec 12, 2019 Alphamab Oncology (HK: 9966) is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of therapeutics …See details»
3D Medicines, Simcere and Alphamab Oncology Announced …
Alphamab Oncology is a biopharmaceutical company focusing on the research and development, manufacturing and commercialization of biologics for oncology. On December 12, 2019, the …See details»
Alphamab Oncology - Recent News & Activity - Crunchbase
Nov 11, 2024 Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization. Search Crunchbase. Start …See details»
Alphamab Oncology's Anti-Tumor Drug Gets IND Approval from …
Dec 25, 2024 Alphamab Oncology is an investment holding company principally engaged in research and development, manufacturing and commercialisation of biologics of oncology. …See details»
Alphamab Oncology Company Profile - Office Locations ... - Craft
Alphamab Oncology has 1 employees across 3 locations and $160 m in total funding,. See insights on Alphamab Oncology including office locations, competitors, revenue, financials, …See details»
Alphamab Oncology Update
Jiangsu Alphamab, as the study sponsor, will oversee and run the trial, and Pfizer will supply palbociclib. [View details] KN046 Update 2 1 Alphamab Oncology and InxMed Announce Partnership to Develop Combination Therapy of KN046 and IN10018 May 23, 2020 Alphamab Oncology has entered a partnership agreement with InxMed (Shanghai) Co., Ltd., to ...See details»
Alphamab Oncology Presented the Phase II Clinical Data of KN046 …
Dec 13, 2024 Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from a phase II clinical study on PD-L1/CTLA-4 bispecific antibody KN046 in combination with …See details»
Late-Breaking Abstract! Alphamab Oncology Presented the Latest …
Nov 11, 2024 Alphamab Oncology (stock code: 9966.HK) announced that the results of the first-in-human clinical study of JSKN033, a high-concentration subcutaneous co-formulation …See details»
Alphamab Oncology Announced Anti-HER2 Bispecific ADC …
Dec 30, 2024 Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug …See details»
Dr. Farn Chan, MD | Woodbridge, VA | Oncologist | US News Doctors
Dr. Farn Chan is a Oncologist in Woodbridge, VA. Find Dr. Chan's phone number, address, insurance information, hospital affiliations and more.See details»
Alphamab Oncology Presented the Latest Clinical Data from Two …
Sep 16, 2024 Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 were …See details»
Alphamab Oncology - Contacts, Employees, Board Members
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization. Search Crunchbase Start Free TrialSee details»
POTOMAC RADIATION ONCOLOGY CENTER NPI 1013181791 …
Apr 15, 2008 NPI Profile for Potomac Radiation Oncology Center in 2296 Opitz Blvd Suite 140 Woodbridge, Va 22191. Phone: (703) 670-3349 . Taxonomy 261QX0203X Accepts: Medicare, …See details»
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 …
2 days ago Data reported by ABL Bio at the annual meeting of the American Society of Clinical Oncology ("ASCO 2024") showed promising objective responses in patients with various solid …See details»
I-Mab | I-Mab Announces Portfolio Prioritization of Givastomig …
Sep 30, 2024 Topline Phase 1 monotherapy dose escalation and dose expansion data presented at the annual meeting of the European Society for Medical Oncology ("ESMO …See details»
Sociobiology meets oncology: unraveling altruistic cooperation in ...
2 days ago Oncology Studying cooperation among microbes has led to important medical insights, such as the development of antibiotic resistance 10 , 82 , biofilm formation 83 , and …See details»